Annals of Laboratory Medicine

Korean Society for Laboratory Medicine (대한진단검사의학회)
권호 표지
DOI QR코드

DOI QR Code

Current Challenges in Chimeric Antigen Receptor T-cell Therapy in Patients With B-cell Lymphoid Malignancies

  • Seok Jin Kim (Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Sang Eun Yoon (Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Won Seog Kim (Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine)
  • Received : 2023.09.30
  • Accepted : 2023.12.29
  • Published : 2024.05.01
Download PDF
⟨ Previous Next ⟩

Abstract

Chimeric antigen receptor (CAR) T-cell therapy is a promising immunotherapy based on genetically engineered T cells derived from patients. The introduction of CAR T-cell therapy has changed the treatment paradigm of patients with B-cell lymphoid malignancies. However, challenging issues including managing life-threatening toxicities related to CAR T-cell infusion and resistance to CAR T-cell therapy, leading to progression or relapse, remain. This review summarizes the issues with currently approved CAR T-cell therapies for patients with relapsed or refractory B-cell lymphoid malignancies, including lymphoma and myeloma. We focus on unique toxicities after CAR T-cell therapy, such as cytokine-related events and hematological toxicities, and the mechanisms underlying post-CAR T-cell failure.

Keywords

Acknowledgement

This research was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute, funded by the Ministry of Health and Welfare of the Republic of Korea (grant number: HR20C0025) and by a National Research Foundation of Korea grant funded by the Korean government (2021R1A2C1007531).

References

  1. Ramos CA and Dotti G. Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy. Expert Opin Biol Ther 2011;11:855-73. https://doi.org/10.1517/14712598.2011.573476
  2. Zhang C, Liu J, Zhong JF, Zhang X. Engineering CAR-T cells. Biomark Res 2017;5:22. https://doi.org/10.1186/s40364-017-0102-y
  3. Jackson HJ, Rafiq S, Brentjens RJ. Driving CAR T-cells forward. Nat Rev Clin Oncol 2016;13:370-83. https://doi.org/10.1038/nrclinonc.2016.36
  4. Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 2019;380:45-56. https://doi.org/10.1056/NEJMoa1804980
  5. Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med 2018;378:439-48. https://doi.org/10.1056/NEJMoa1709866
  6. Fowler NH, Dickinson M, Dreyling M, Martinez-Lopez J, Kolstad A, Butler J, et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med 2022;28:325-32. https://doi.org/10.1038/s41591-021-01622-0
  7. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 2017;377:2531-44. https://doi.org/10.1056/NEJMoa1707447
  8. Jacobson CA, Chavez JC, Sehgal AR, William BM, Munoz J, Salles G, et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol 2022;23:91-103. https://doi.org/10.1016/S1470-2045(21)00591-X
  9. Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet 2021;398:491-502. https://doi.org/10.1016/S0140-6736(21)01222-8
  10. Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2020;382:1331-42. https://doi.org/10.1056/NEJMoa1914347
  11. Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 2020;396:839-52. https://doi.org/10.1016/S0140-6736(20)31366-0
  12. Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med 2022;386:640-54. https://doi.org/10.1056/NEJMoa2116133
  13. Kamdar M, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an openlabel, randomised, phase 3 trial. Lancet 2022;399:2294-308. https://doi.org/10.1016/S0140-6736(22)00662-6
  14. Munshi NC, Anderson LD, Jr., Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med 2021;384:705-16. https://doi.org/10.1056/NEJMoa2024850
  15. Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet 2021;398:314-24. https://doi.org/10.1016/S0140-6736(21)00933-8
  16. Bücklein V, Perez A, Rejeski K, Iacoboni G, Jurinovic V, Holtick U, et al. Inferior outcomes of EU versus US patients treated with CD19 CAR-T for relapsed/refractory large B-cell lymphoma: association with differences in tumor burden, systemic inflammation, bridging therapy utilization, and CAR-T product use. Hemasphere 2023;7:e907. https://doi.org/10.1097/HS9.0000000000000907
  17. Hoffmann MS, Hunter BD, Cobb PW, Varela JC, Munoz J. Overcoming barriers to referral for chimeric antigen receptor T cell therapy in patients with relapsed/refractory diffuse large B cell lymphoma. Transplant Cell Ther 2023;29:440-8. https://doi.org/10.1016/j.jtct.2023.04.003
  18. Bethge WA, Martus P, Schmitt M, Holtick U, Subklewe M, von Tresckow B, et al. GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany. Blood 2022;140:349-58. https://doi.org/10.1182/blood.2021015209
  19. Zafar A, Huang CY, Lo M, Arora S, Chung A, Wong SW, et al. Intensity of cyclophosphamide-based bridging therapy before chimeric antigen receptor T cell therapy in myeloma. Transplant Cell Ther 2023;29:504e1-7. https://doi.org/10.1016/j.jtct.2023.05.016
  20. Ladbury C, Dandapani S, Hao C, Fabros M, Amini A, Sampath S, et al. Long-term follow-up of bridging therapies prior to CAR T-cell therapy for relapsed/refractory large B cell lymphoma. Cancers (Basel) 2023;15:1747. https://doi.org/10.3390/cancers15061747
  21. Roddie C, Neill L, Osborne W, Iyengar S, Tholouli E, Irvine D, et al. Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma. Blood Adv 2023;7:2872-83. https://doi.org/10.1182/bloodadvances.2022009019
  22. Hirayama AV, Gauthier J, Hay KA, Voutsinas JM, Wu Q, Gooley T, et al. The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. Blood 2019;133:1876-87. https://doi.org/10.1182/blood-2018-11-887067
  23. Byun JM. Practical issues in CAR T-cell therapy. Blood Res 2023;58:S11-2. https://doi.org/10.5045/br.2023.2023015
  24. Fried S, Avigdor A, Bielorai B, Meir A, Besser MJ, Schachter J, et al. Early and late hematologic toxicity following CD19 CAR-T cells. Bone Marrow Transplant 2019;54:1643-50. https://doi.org/10.1038/s41409-019-0487-3
  25. Yoo JW. Management of adverse events in young adults and children with acute B-cell lymphoblastic leukemia receiving anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. Blood Res 2023;58:S20-8. https://doi.org/10.5045/br.2023.2023026
  26. Li Y, Ming Y, Fu R, Li C, Wu Y, Jiang T, et al. The pathogenesis, diagnosis, prevention, and treatment of CAR-T cell therapy-related adverse reactions. Front Pharmacol 2022;13:950923. https://doi.org/10.3389/fphar.2022.950923
  27. Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, et al. Chimeric antigen receptor T-cell therapy — assessment and management of toxicities. Nat Rev Clin Oncol 2018;15:47-62. https://doi.org/10.1038/nrclinonc.2017.148
  28. Norelli M, Camisa B, Barbiera G, Falcone L, Purevdorj A, Genua M, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med 2018;24:739-48. https://doi.org/10.1038/s41591-018-0036-4
  29. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013;368:1509-18. https://doi.org/10.1056/NEJMoa1215134
  30. Si S and Teachey DT. Spotlight on tocilizumab in the treatment of CAR-Tcell-induced cytokine release syndrome: clinical evidence to date. Ther Clin Risk Manag 2020;16:705-14.
  31. Le RQ, Li L, Yuan W, Shord SS, Nie L, Habtemariam BA, et al. FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. Oncologist 2018;23:943-7. https://doi.org/10.1634/theoncologist.2018-0028
  32. Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 2019;25:625-38. https://doi.org/10.1016/j.bbmt.2018.12.758
  33. Santomasso BD, Nastoupil LJ, Adkins S, Lacchetti C, Schneider BJ, Anadkat M, et al. Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO Guideline. J Clin Oncol 2021;39:3978-92. https://doi.org/10.1200/JCO.21.01992
  34. Santomasso BD, Park JH, Salloum D, Riviere I, Flynn J, Mead E, et al. Clinical and biological correlates of neurotoxicity associated with CAR Tcell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov 2018;8:958-71. https://doi.org/10.1158/2159-8290.CD-17-1319
  35. Freyer CW and Porter DL. Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies. J Allergy Clin Immunol 2020;146:940-8. https://doi.org/10.1016/j.jaci.2020.07.025
  36. Gust J, Hay KA, Hanafi LA, Li D, Myerson D, Gonzalez-Cuyar LF, et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov 2017;7:1404-19. https://doi.org/10.1158/2159-8290.CD-17-0698
  37. Gust J, Ponce R, Liles WC, Garden GA, Turtle CJ. Cytokines in CAR T cellassociated neurotoxicity. Front Immunol 2020;11:577027. https://doi.org/10.3389/fimmu.2020.577027
  38. Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 2015;385:517-28. https://doi.org/10.1016/S0140-6736(14)61403-3
  39. Nastoupil LJ, Jain MD, Feng L, Spiegel JY, Ghobadi A, Lin Y, et al. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large Bcell lymphoma: results from the US lymphoma CAR T Consortium. J Clin Oncol 2020;38:3119-28. https://doi.org/10.1200/JCO.19.02104
  40. Holtzman NG, Xie H, Bentzen S, Kesari V, Bukhari A, El Chaer F, et al. Immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes. Neuro Oncol 2021;23:112-21. https://doi.org/10.1093/neuonc/noaa183
  41. Nellan A, McCully CML, Cruz Garcia R, Jayaprakash N, Widemann BC, Lee DW, et al. Improved CNS exposure to tocilizumab after cerebrospinal fluid compared to intravenous administration in rhesus macaques. Blood 2018;132:662-6. https://doi.org/10.1182/blood-2018-05-846428
  42. Neelapu SS. Managing the toxicities of CAR T-cell therapy. Hematol Oncol 2019;37 Suppl 1:48-52. https://doi.org/10.1002/hon.2595
  43. Schubert ML, Schmitt M, Wang L, Ramos CA, Jordan K, Müller-Tidow C, et al. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Ann Oncol 2021;32:34-48. https://doi.org/10.1016/j.annonc.2020.10.478
  44. Topp MS, van Meerten T, Houot R, Minnema MC, Bouabdallah K, Lugtenburg PJ, et al. Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. Br J Haematol 2021;195:388-98. https://doi.org/10.1111/bjh.17673
  45. Wehrli M, Gallagher K, Chen YB, Leick MB, McAfee SL, El-Jawahri AR, et al. Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS). J Immunother Cancer 2022;10:e003847. https://doi.org/10.1136/jitc-2021-003847
  46. Riegler LL, Jones GP, Lee DW. Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy. Ther Clin Risk Manag 2019;15:323-35. https://doi.org/10.2147/TCRM.S150524
  47. Hines MR, Keenan C, Maron Alfaro G, Cheng C, Zhou Y, Sharma A, et al. Hemophagocytic lymphohistiocytosis-like toxicity (carHLH) after CD19-specific CAR T-cell therapy. Br J Haematol 2021;194:701-7. https://doi.org/10.1111/bjh.17662
  48. Major A, Collins J, Craney C, Heitman AK, Bauer E, Zerante E, et al. Management of hemophagocytic lymphohistiocytosis (HLH) associated with chimeric antigen receptor T-cell (CAR-T) therapy using anti-cytokine therapy: an illustrative case and review of the literature. Leuk Lymphoma 2021;62:1765-9. https://doi.org/10.1080/10428194.2021.1881507
  49. Hines MR, Knight TE, McNerney KO, Leick MB, Jain T, Ahmed S, et al. Immune effector cell-associated hemophagocytic lymphohistiocytosislike syndrome. Transplant Cell Ther 2023;29:438.e1-16.
  50. Henter JI, Samuelsson-Horne A, Aricò M, Egeler RM, Elinder G, Filipovich AH, et al. Treatment of hemophagocytic lymphohistiocytosis with HLH94 immunochemotherapy and bone marrow transplantation. Blood 2002;100:2367-73. https://doi.org/10.1182/blood-2002-01-0172
  51. Rosado FGN and Kim AS. Hemophagocytic lymphohistiocytosis: an update on diagnosis and pathogenesis. Am J Clinical Pathol 2013;139:713-27. https://doi.org/10.1309/AJCP4ZDKJ4ICOUAT
  52. Sandler RD, Tattersall RS, Schoemans H, Greco R, Badoglio M, Labopin M, et al. Diagnosis and management of secondary HLH/MAS following HSCT and CAR-T cell therapy in adults; a review of the literature and a survey of practice within EBMT centres on behalf of the autoimmune diseases working party (ADWP) and transplant complications working party (TCWP). Front Immunol 2020;11:524. https://doi.org/10.3389/fimmu.2020.00524
  53. Henter JI, Horne A, Aricó M, Egeler RM, Filipovich AH, Imashuku S, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007;48:124-31. https://doi.org/10.1002/pbc.21039
  54. Daver N and Kantarjian H. Malignancy-associated haemophagocytic lymphohistiocytosis in adults. Lancet Oncol 2017;18:169-71. https://doi.org/10.1016/S1470-2045(17)30004-9
  55. Yoon SE, Eun Y, Huh K, Chung CR, Yoo IY, Cho J, et al. A comprehensive analysis of adult patients with secondary hemophagocytic lymphohistiocytosis: a prospective cohort study. Ann Hematol 2020;99:2095-104. https://doi.org/10.1007/s00277-020-04083-6
  56. Thompson JA, Schneider BJ, Brahmer J, Achufusi A, Armand P, Berkenstock MK, et al. Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2022;20:387-405. https://doi.org/10.6004/jnccn.2022.0020
  57. Rainone M, Ngo D, Baird JH, Budde LE, Htut M, Aldoss I, et al. Interferongamma blockade in CAR T-cell therapy-associated macrophage activation syndrome/hemophagocytic lymphohistiocytosis. Blood Adv 2023;7:533-6. https://doi.org/10.1182/bloodadvances.2022008256
  58. La Rosée P, Horne A, Hines M, von Bahr Greenwood T, Machowicz R, Berliner N, et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood 2019;133:2465-77. https://doi.org/10.1182/blood.2018894618
  59. Nahas GR, Komanduri KV, Pereira D, Goodman M, Jimenez AM, Beitinjaneh A, et al. Incidence and risk factors associated with a syndrome of persistent cytopenias after CAR-T cell therapy (PCTT). Leuk Lymphoma 2020;61:940-3. https://doi.org/10.1080/10428194.2019.1697814
  60. Jain T, Olson TS, Locke FL. How I treat cytopenias after CAR T-cell therapy. Blood 2023;141:2460-9. https://doi.org/10.1182/blood.2022017415
  61. Juluri KR, Wu QV, Voutsinas J, Hou J, Hirayama AV, Mullane E, et al. Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy. Blood Adv 2022;6:2055-68. https://doi.org/10.1182/bloodadvances.2020004142
  62. Rejeski K, Wu Z, Blumenberg V, Kunz WG, Müller S, Kajigaya S, et al. Oligoclonal T-cell expansion in a patient with bone marrow failure after CD19 CAR-T therapy for Richter-transformed DLBCL. Blood 2022;140:2175-9. https://doi.org/10.1182/blood.2022017015
  63. Rejeski K, Perez A, Sesques P, Hoster E, Berger C, Jentzsch L, et al. CARHEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma. Blood 2021;138:2499-513. https://doi.org/10.1182/blood.2020010543
  64. Rejeski K, Perez A, Iacoboni G, Penack O, Bücklein V, Jentzsch L, et al. The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL. J Immunother Cancer 2022;10:e004475. https://doi.org/10.1136/jitc-2021-004475
  65. Rejeski K, Subklewe M, Aljurf M, Bachy E, Balduzzi A, Barba P, et al. Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations. Blood 2023;142:865-77. https://doi.org/10.1182/blood.2023020578
  66. Galli E, Allain V, Di Blasi R, Bernard S, Vercellino L, Morin F, et al. G-CSF does not worsen toxicities and efficacy of CAR-T cells in refractory/relapsed B-cell lymphoma. Bone Marrow Transplant 2020;55:2347-9. https://doi.org/10.1038/s41409-020-01006-x
  67. Liévin R, Di Blasi R, Morin F, Galli E, Allain V, De Jorna R, et al. Effect of early granulocyte-colony-stimulating factor administration in the prevention of febrile neutropenia and impact on toxicity and efficacy of anti-CD19 CAR-T in patients with relapsed/refractory B-cell lymphoma. Bone Marrow Transplant 2022;57:431-9. https://doi.org/10.1038/s41409-021-01526-0
  68. Lemoine J, Bachy E, Cartron G, Beauvais D, Gastinne T, Di Blasi R, et al. Non-relapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T Registry. Blood Adv 2023;7:6589-98. https://doi.org/10.1182/bloodadvances.2023010624
  69. Bivona G, Agnello L, Ciaccio M. Biomarkers for prognosis and treatment response in COVID-19 patients. Ann Lab Med 2021;41:540-8. https://doi.org/10.3343/alm.2021.41.6.540
  70. Harris CE, Vijenthira A, Ong SY, Baden LR, Hicks LK, Baird JH. COVID-19 and other viral infections in patients with hematologic malignancies. Am Soc Clin Oncol Educ Book 2023;43:e390778. https://doi.org/10.1200/EDBK_390778
  71. Shalabi H, Kraft IL, Wang HW, Yuan CM, Yates B, Delbrook C, et al. Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma. Haematologica 2018;103:e215-8. https://doi.org/10.3324/haematol.2017.183459
  72. Plaks V, Rossi JM, Chou J, Wang L, Poddar S, Han G, et al. CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel. Blood 2021;138:1081-5. https://doi.org/10.1182/blood.2021010930
  73. Shah NN, Lee DW, Yates B, Yuan CM, Shalabi H, Martin S, et al. Longterm follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL. J Clin Oncol 2021;39:1650-9. https://doi.org/10.1200/JCO.20.02262
  74. Park JH, Rivière I, Gonen M, Wang X, Sénéchal B, Curran KJ, et al. Longterm follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med 2018;378:449-59. https://doi.org/10.1056/NEJMoa1709919
  75. Myers RM, Taraseviciute A, Steinberg SM, Lamble AJ, Sheppard J, Yates B, et al. Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL. J Clin Oncol 2022;40:932-44. https://doi.org/10.1200/JCO.21.01405
  76. Singh N, Lee YG, Shestova O, Ravikumar P, Hayer KE, Hong SJ, et al. Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T-cell dysfunction. Cancer Discov 2020;10:552-67. https://doi.org/10.1158/2159-8290.CD-19-0813
  77. Dekker L, Calkoen FG, Jiang Y, Blok H, Veldkamp SR, De Koning C, et al. Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia. Blood Adv 2022;6:1969-76. https://doi.org/10.1182/bloodadvances.2021006700
  78. Jain MD, Zhao H, Wang X, Atkins R, Menges M, Reid K, et al. Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma. Blood 2021;137:2621-33. https://doi.org/10.1182/blood.2020007445
  79. Mehta PH, Fiorenza S, Koldej RM, Jaworowski A, Ritchie DS, Quinn KM. T cell fitness and autologous CAR T cell therapy in haematologic malignancy. Front Immunol 2021;12:780442. https://doi.org/10.3389/fimmu.2021.780442
  80. Scholler N, Perbost R, Locke FL, Jain MD, Turcan S, Danan C, et al. Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma. Nat Med 2022;28:1872-82. https://doi.org/10.1038/s41591-022-01916-x
  81. Deng Q, Han G, Puebla-Osorio N, Ma MCJ, Strati P, Chasen B, et al. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nat Med 2020;26:1878-87. https://doi.org/10.1038/s41591-020-1061-7
  82. Sommermeyer D, Hudecek M, Kosasih PL, Gogishvili T, Maloney DG, Turtle CJ, et al. Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. Leukemia 2016;30:492-500. https://doi.org/10.1038/leu.2015.247
  83. Gattinoni L, Lugli E, Ji Y, Pos Z, Paulos CM, Quigley MF, et al. A human memory T cell subset with stem cell-like properties. Nat Med 2011;17:1290-7. https://doi.org/10.1038/nm.2446
  84. Gattinoni L, Speiser DE, Lichterfeld M, Bonini C. T memory stem cells in health and disease. Nat Med 2017;23:18-27. https://doi.org/10.1038/nm.4241
  85. Alvarez-Fernàndez C, Escribà-Garcia L, Caballero AC, Escudero-López E, Ujaldón-Miró C, Montserrat-Torres R, et al. Memory stem T cells modified with a redesigned CD30-chimeric antigen receptor show an enhanced antitumor effect in Hodgkin lymphoma. Clin Transl Immunology 2021;10:e1268. https://doi.org/10.1002/cti2.1268
  86. Locke FL, Rossi JM, Neelapu SS, Jacobson CA, Miklos DB, Ghobadi A, et al. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv 2020;4:4898-911. https://doi.org/10.1182/bloodadvances.2020002394
  87. Aldoss I, Khaled SK, Wang X, Palmer J, Wang Y, Wagner JR, et al. Favorable activity and safety profile of memory-enriched CD19-targeted chimeric antigen receptor T-cell therapy in adults with high-risk relapsed/refractory ALL. Clin Cancer Res 2023;29:742-53. https://doi.org/10.1158/1078-0432.CCR-22-2038